MX2020004896A - Formulaciones de linezolid. - Google Patents

Formulaciones de linezolid.

Info

Publication number
MX2020004896A
MX2020004896A MX2020004896A MX2020004896A MX2020004896A MX 2020004896 A MX2020004896 A MX 2020004896A MX 2020004896 A MX2020004896 A MX 2020004896A MX 2020004896 A MX2020004896 A MX 2020004896A MX 2020004896 A MX2020004896 A MX 2020004896A
Authority
MX
Mexico
Prior art keywords
linezolid
formulations
linezolid formulations
clp
alleviating
Prior art date
Application number
MX2020004896A
Other languages
English (en)
Inventor
Lloyd Czaplewski
Sarah Guest
Original Assignee
Persica Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Persica Pharmaceuticals Ltd filed Critical Persica Pharmaceuticals Ltd
Publication of MX2020004896A publication Critical patent/MX2020004896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a composiciones de hidrogel termosensibles inyectables que comprenden linezolid para aliviar y/o tratar el dolor lumbar crónico (DLC).
MX2020004896A 2017-11-16 2018-11-16 Formulaciones de linezolid. MX2020004896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587101P 2017-11-16 2017-11-16
PCT/GB2018/053319 WO2019097242A1 (en) 2017-11-16 2018-11-16 Linezolid formulations

Publications (1)

Publication Number Publication Date
MX2020004896A true MX2020004896A (es) 2020-10-19

Family

ID=64457035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004896A MX2020004896A (es) 2017-11-16 2018-11-16 Formulaciones de linezolid.

Country Status (16)

Country Link
US (3) US11517574B2 (es)
EP (2) EP3709970B1 (es)
JP (3) JP7251813B2 (es)
KR (1) KR102787942B1 (es)
CN (1) CN111432800B (es)
AU (1) AU2018369696B2 (es)
CA (1) CA3081449A1 (es)
DK (1) DK3709970T3 (es)
ES (1) ES3034187T3 (es)
FI (1) FI3709970T3 (es)
MX (1) MX2020004896A (es)
PL (1) PL3709970T3 (es)
RU (1) RU2771279C2 (es)
SG (1) SG11202003537TA (es)
TW (1) TWI835758B (es)
WO (1) WO2019097242A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3541442T3 (da) * 2016-11-16 2022-03-14 Persica Pharmaceuticals Ltd Antibiotiske formuleringer mod lændesmerter
DK3709970T3 (da) * 2017-11-16 2025-07-07 Persica Pharmaceuticals Ltd Linezolidformuleringer
WO2022115568A1 (en) * 2020-11-24 2022-06-02 Discgenics, Inc. Methods and systems for treatment of intervertebral disc by intradiscal micro-needle insertion cross reference to related applications
CN112451475B (zh) * 2020-12-02 2022-04-05 深圳善康医疗健康产业有限公司 一种用于治疗空洞型肺结核的长效缓释凝胶
WO2023062080A1 (en) 2021-10-12 2023-04-20 Persica Pharmaceuticals Ltd. Low back pain treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5628734A (en) 1995-03-23 1997-05-13 Hatfalvi; Bela I. Spinal needle with curved distal end and method of using said needle in a spinal injection to prevent post dural puncture headache
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US6803485B2 (en) 1999-02-26 2004-10-12 Bracco Imaging S.P.A. Process for the preparation of iopamidol
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
AR027261A1 (es) * 2000-02-02 2003-03-19 Upjohn Co Linezolid forma cristalina ii
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US6500153B1 (en) 2001-07-13 2002-12-31 Children's And Women's Health Centre Of British Columbia Syringe and needle for preventing inadvertent drug injection
AU2004224439B2 (en) * 2003-03-24 2010-07-15 Genzyme Corporation Temporary embolization using inverse thermosensitive polymers
WO2005032650A1 (en) 2003-10-03 2005-04-14 Medtronic, Inc. Kit for implantation of therapy elements
US20050143678A1 (en) * 2003-10-14 2005-06-30 Pluromed, Inc. Confinement of kidney-stone fragments during lithotripsy
PT1673370E (pt) 2003-10-16 2009-11-05 Symed Labs Ltd Forma cristalina de linezolida
CA2572207A1 (en) 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd. Solid forms of linezolid and processes for preparation thereof
US20060142283A1 (en) 2004-06-29 2006-06-29 Judith Aronhime Crystalline form IV of linezolid
US7367961B2 (en) 2004-09-10 2008-05-06 Depuy Spine, Inc. Intradiscal injection of autologous interferon
US7850656B2 (en) 2005-04-29 2010-12-14 Warsaw Orthopedic, Inc. Devices and methods for delivering medical agents
US20070104785A1 (en) 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
WO2007026369A1 (en) 2005-08-29 2007-03-08 Symed Labs Limited A novel amorphous form of linezolid
CN102112112A (zh) 2008-07-21 2011-06-29 奥德纳米有限公司 用于治疗耳部病症的受控释放抗微生物组合物和方法
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2490722A4 (en) 2009-10-21 2014-03-05 Otonomy Inc MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
US9132207B2 (en) 2009-10-27 2015-09-15 Spine Wave, Inc. Radiopaque injectable nucleus hydrogel compositions
US10227289B2 (en) 2010-05-07 2019-03-12 Medicus Biosciences, Llc Methods for treating diseases of the lung
PL2394663T3 (pl) * 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
CN102988274B (zh) * 2010-09-08 2015-01-28 上海市肿瘤研究所 用于治疗肿瘤的药物缓释血管栓塞凝胶剂及其制备方法
US20120101593A1 (en) * 2010-10-20 2012-04-26 BIOS2 Medical, Inc. Implantable polymer for bone and vascular lesions
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
EP2606912A1 (en) 2011-12-23 2013-06-26 Central Medical Service Co., Ltd. Contrast medium composition with contrast enhancement effect by comprising highly concentrated agent
WO2014013498A1 (en) 2012-07-17 2014-01-23 Symed Labs Limited Amorphous coprecipitates of linezolid
US9610396B2 (en) 2013-03-15 2017-04-04 Thermedical, Inc. Systems and methods for visualizing fluid enhanced ablation therapy
ITMI20131755A1 (it) * 2013-10-21 2015-04-22 Mero S R L Composizione bioriassorbibile contenente agenti antibatterici per il trattamento del dolore lombare
EP3099345B1 (en) 2014-01-31 2018-10-10 Cedars-Sinai Medical Center Pigtail for optimal aortic valvular complex imaging and alignment
US10189870B2 (en) 2014-04-18 2019-01-29 Hangzhou Pushai Pharmaeutical Technology Co., Ltd. Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof
CN104586768A (zh) * 2014-12-30 2015-05-06 亚邦医药股份有限公司 一种含利奈唑胺的抗感染药用组合物及其制备方法
JP2018523492A (ja) 2015-07-24 2018-08-23 ディシティスディーエックス インコーポレイテッド 低毒性感染症の検出及び治療方法
DK3541442T3 (da) * 2016-11-16 2022-03-14 Persica Pharmaceuticals Ltd Antibiotiske formuleringer mod lændesmerter
WO2019060869A1 (en) 2017-09-25 2019-03-28 Discitisdx, Inc. METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOMBALGIA
DK3709970T3 (da) 2017-11-16 2025-07-07 Persica Pharmaceuticals Ltd Linezolidformuleringer

Also Published As

Publication number Publication date
US20200352952A1 (en) 2020-11-12
CN111432800B (zh) 2023-12-15
TW201932112A (zh) 2019-08-16
EP3709970B1 (en) 2025-05-14
DK3709970T3 (da) 2025-07-07
ES3034187T3 (en) 2025-08-13
JP7251813B2 (ja) 2023-04-04
PL3709970T3 (pl) 2025-09-08
EP4616848A2 (en) 2025-09-17
JP2021503462A (ja) 2021-02-12
EP3709970A1 (en) 2020-09-23
FI3709970T3 (fi) 2025-08-13
RU2020115866A (ru) 2021-12-16
JP7607962B2 (ja) 2025-01-06
EP4616848A3 (en) 2025-11-12
JP2025032268A (ja) 2025-03-11
AU2018369696B2 (en) 2024-02-01
CN111432800A (zh) 2020-07-17
TWI835758B (zh) 2024-03-21
US20230143410A1 (en) 2023-05-11
RU2771279C2 (ru) 2022-04-29
CA3081449A1 (en) 2019-05-23
SG11202003537TA (en) 2020-05-28
RU2020115866A3 (es) 2021-12-16
AU2018369696A1 (en) 2020-06-04
KR102787942B1 (ko) 2025-03-31
JP2023075287A (ja) 2023-05-30
KR20200088328A (ko) 2020-07-22
WO2019097242A1 (en) 2019-05-23
US11517574B2 (en) 2022-12-06
US20250152597A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
MX2020004896A (es) Formulaciones de linezolid.
MX2020012295A (es) Composiciones de fusosoma y usos de estas.
MX2021000308A (es) Composiciones de fusosoma y usos de estas.
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
SV2018005643A (es) Composiciones de insulina de rapida accion
MX370963B (es) Composiciones para el cuidado personal.
MX2021006943A (es) Anelosomas para suministrar modalidades terapéuticas secretadas.
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
MX374111B (es) Composiciones con fragancia de liberación prolongada.
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
BR112015022587A2 (pt) formulações de citocina quimérica para entrega ocular
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
BR112018010705A2 (pt) vacinação com o domínio mica/b alfa 3 para o tratamento de câncer
BR112017024672B8 (pt) Kit de inserção de um implante endósseo unitário
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
CL2016002779A1 (es) Composición para el cuidado de la piel
MX2018014135A (es) Tratamiento del dolor.
MX2017013879A (es) Composiciones que comprenden anakinra.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
BR112017028400A2 (pt) composições líquidas para dispositivos de remoção de pelos
MX2020006282A (es) Una composicion antimicrobiana.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação